Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Short, S.
Right arrow Articles by Jungmann, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Short, S.
Right arrow Articles by Jungmann, R. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 275, Issue 17, 12963-12969, April 28, 2000


Structural Determinants for Post-transcriptional Stabilization of Lactate Dehydrogenase A mRNA by the Protein Kinase C Signal Pathway*

Sabine Short, Di Tian, Marc L. Short, and Richard A. JungmannDagger

From the Department of Cellular and Molecular Biology and Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611-3008

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Activation of protein kinase C (PKC) and protein kinase A (PKA) in rat C6 glioma cells increases the half-life of short-lived lactate dehydrogenase (LDH)-A mRNA about 5- and 8-fold, respectively. PKA and PKC act synergistically and prolong LDH-A mRNA half-life more than 21-fold. Similar effects were observed after transfection and transcription of a globin/lactate dehydrogenase minigene consisting of a beta -globin expression vector in which the 3'-untranslated region (UTR) of beta -globin had been replaced with the LDH-A 3'-UTR. Synergism was only obtained by transcription of minigenes containing the entire 3'-UTR and did not occur when truncated 3'-UTR fragments were analyzed. Additional mutational analyses showed that a 20-nucleotide region, named PKC-stabilizing region (PCSR), is responsible for mediating the stabilizing effect of PKC. Previous studies (Tian, D., Huang, D., Short, S., Short, M. L., and Jungmann, R. A. (1998) J. Biol. Chem. 273, 24861-24866) have demonstrated the existence of a cAMP-stabilizing region in LDH-A 3'-UTR. Sequence analysis of PCSR identified a 13-nucleotide AU-rich region that is common to both cAMP-stabilizing region and PCSR. These studies identify a specific PKC-responsive stabilizing element and indicate that interaction of PKA and PKC results in a potentiating effect on LDH-A mRNA stabilization.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

During recent years we have established evidence for a bimodal mechanism of LDH-A1 regulation involving transcriptional as well as post-transcriptional modulation of LDH-A expression (1-6). Both mechanisms are regulated by a number of agonists of intracellular signaling pathways. For instance, agonists of PKA and PKC can modify the metabolic functions of cells by inducing an altered program of LDH-A mRNA regulation. These mechanisms allow the cell to respond rapidly to changes in the physiologic environment of the cell and to cover a potential energy deficit through conversion of pyruvate to lactate. Clues to mechanisms underlying this dual mode of control were provided by the identification of cis-acting promoter elements instrumental in PKA- and PKC-mediated transcriptional regulation (2, 6). However, less information is available about the mechanism of protein kinase-mediated LDH-A mRNA stability regulation resulting in higher levels of intracellular LDH-A mRNA (3).

Attention has recently focused on the modulation of mRNA stability in response to a variety of physiological signals. For instance, it is known that activators of PKA and PKC are important effectors of mRNA stability regulation in a number of gene systems (1, 3, 5, 7-14). Our own studies identified a synergistic interaction between PKA and PKC in regulating the stability of LDH-A mRNA (3). Whereas the molecular basis for the synergistic effect remains unknown, we have recently identified a cAMP-stabilizing region (CSR) within the 3'-UTR of LDH-A mRNA (5) that in combination with specific CSR-binding proteins (4) is required to achieve LDH-A mRNA stabilization in response to PKA activation. The binding activity of the proteins to the CSR and the effect on LDH-A mRNA stabilization are regulated through a phosphorylation/dephosphorylation mechanism by PKA and as yet unknown protein phosphatases. Thus, it is now clear that the CSR, in concert with CSR-binding proteins, is absolutely required to achieve increased LDH-A mRNA stability in response to PKA activation. However, the molecular mechanism of mRNA stabilization by PKC is unknown.

The present paper describes the identification of a cis-regulatory element within the 3'-UTR of LDH-A mRNA that is required for PKC-mediated mRNA stability regulation. The identification was accomplished using a strategy previously developed for the identification of the cAMP-stabilizing region (5). Using deletion, mutation, and replacement analysis, we constructed chimeric beta -globin/ldh 3'-UTR minigenes that were stably transfected and expressed in rat C6 glioma cells. Applying ribonuclease protection assays, we studied the effects of PKC activation on the rate of decay of chimeric beta -globin/ldh 3'-UTR mRNAs. Using this methodology, we demonstrated the presence of an uridine-rich region within the LDH-A 3'-UTR, named PKC-stabilizing region (PCSR), capable of stabilizing LDH-A mRNA in response PKC activation. It is of particular interest that the sequences of CSR and PCSR overlap and possess a common 13-nucleotide region.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Nucleic acid-modifying enzymes, acrylamide, and nucleoside triphosphates were from Roche Molecular Biochemicals. Radioisotopes were purchased from NEN Life Science Products. Other reagents were of molecular biology grade and purchased from Sigma. Cell culture products were purchased from Life Technologies, Inc.

Synthetic Oligonucleotides-- Synthesis and processing of synthetic DNA oligonucleotides and their ligation into respective plasmid vectors were performed as described before (5).

Cell Culture-- Rat C6 glioma cells (American Type Culture Collection CCL 107) were maintained as monolayers in Ham's F-10 nutrient medium supplemented with 10% dialyzed fetal calf serum, 50 units/ml of penicillin, and 50 mg of streptomycin as described by us (5).

Plasmids-- The LDH-A 3'-UTR was derived from plasmid pLDH-2 (kindly provided by Dr. Richard Breathnach) containing a full-length rat fibroblast LDH-A cDNA insert. The mRNA consists of a 103-nucleotide 5'-untranslated region and a 510-nucleotide 3'-untranslated region (corresponding to nucleotides 1103-1610) (50). The 3'-UTR contains the classic polyadenylation signal AAUAAA 18 nucleotides before the poly(A) sequence. A HinfI/BamHI fragment containing the entire LDH-A 3'-UTR (with 28-base pair 5' coding sequence and 100-base pair pLDH-2 vector sequence) was inserted into pGEM3Zf(-) at the BamHI site resulting in plasmid pLDH-5. To eliminate the 28-base pair ldh-a coding and 100-base pair pLDH-2 vector sequences contained in pLDH-5, the complete 510-base pair 3'-UTR of LDH-A with 5' BamHI and 3' HindIII sites was amplified by polymerase chain reaction. The fragment was cloned into the BamHI-HindIII sites of pBluescript II KS+ (Stratagene) resulting in pLDH-6 from which the various 3'-UTR fragments were prepared.

Construction of Wild-type and Mutant Globin/ldh cDNAs-- The rabbit beta -globin expression vector pRc/FBB (see Fig. 1) was constructed as described previously (5) by Dr. D. Chagnovich (Northwestern University) in two steps from plasmids pRc/CMS (Invitrogen) and pBBB (kindly provided by Dr. M. E. Greenberg) (15). Plasmid pRc/FBB encodes a transcription unit consisting of beta -globin coding region flanked by the beta -globin 5'- and 3'-untranslated regions fused to the c-fos promoter.

To construct the chimeric globin/ldh expression vectors, various LDH-A 3'-UTR fragments were inserted into the BglII site or, alternatively, they replaced the BglII/Hind III fragment (beta -globin 3'-UTR) of pRc/FBB. The fragments were constructed as follows. To construct the pRc/FBB expression vector containing the full-length LDH-A 3'-UTR, the 510-base pair 3'-UTR was polymerase chain reaction-amplified from pLDH-6 using 5'- and 3'-oligonucleotide primers with BglII and HindIII restriction sites, respectively. The polymerase chain reaction product as well as pRc/FBB were digested with BglII and HindIII and ligated to generate expression vector pRc/FBB/LDH. In this vector, the beta -globin 3'-UTR had been deleted from pRc/FBB and replaced with the LDH-A 3'-UTR. Truncated 3'-UTR fragments were similarly generated using the appropriate oligonucleotide primers. Fragments for insertion into the BglII site of pRc/FBB were blunt-end ligated, and fragments replacing the globin 3'-UTR contained BglII and HindIII ends.

LDH-A 3'-UTR sequences with base deletions were generated by splicing upstream and downstream polymerase chain reaction fragments that lacked the appropriate base sequence as indicated in Fig. 3. The sequence and correct orientation of all inserts were confirmed by restriction and DNA sequence analyses. Sequencing was carried out in both directions by the dideoxynucleotide chain terminator method with specific synthetic oligonucleotides as primers.

Stable Transfection with Expression Vectors and Selection of G418-resistant Clones-- These experimental methods were described in detail in a previous publication (5).

Cell Stimulation-- All experiments were carried out at about 90% confluence. Serum was withdrawn 24-28 h prior to addition of fetal bovine serum (final concentration, 15%) together with various agents at concentrations indicated in the text. One hour after the addition (taken as 0 h time point), RNA was isolated at subsequent time points up to 12 h and analyzed.

RNA Preparation and mRNA Half-life Measurements-- These methods were previously described in detail (5). Messenger RNA decay was assessed by ribonuclease protection assay. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as internal control, because GAPDH mRNA was stable under the conditions of the experiments regardless of the absence or presence of effector agents.

Nuclear Run-off Assays-- Nuclear run-off experiments were carried out as described by us (1, 3) using a LDH-A 3'-UTR cDNA inserted in Bluescript II KS+ as hybridization probe.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Patterns of Decay and Regulation of Chimeric beta -Globin/ldh mRNA Stability by Protein Kinases A and C Are Identical to Wild-type LDH-A mRNA-- Previous studies in our laboratory demonstrated that intracellular steady-state levels of LDH-A mRNA are regulated, in part, through modulation of mRNA stability. For instance, after treatment of rat glioma cells with activators of PKA or PKC, a dramatic but transient increase of LDH-A mRNA levels takes place (1, 3). The induced mRNA exhibits a markedly increased half-life as compared with the relatively short half-life of LDH-A mRNA in noninduced cells. This indicates that the LDH-A transcript in noninduced cells is targeted for rapid degradation through processes that can be modulated by effector agents capable of activating the PKA or PKC signal transduction pathways.

To investigate the molecular basis of the protein kinase-stabilizing effect, initial studies were carried out to determine whether or not the decay of wild-type LDH-A mRNA and chimeric globin/ldh mRNA followed similar patterns, justifying the use of chimeric vectors for subsequent stability studies. By choosing an expression vector (pRc/FBB) with a serum-inducible c-fos promoter (15-17), we also avoided artifacts that potentially occur when commonly used transcriptional inhibitors (18, 19) are used to stop ongoing transcription. We modified pRc/FBB, which is under the control of a serum-inducible c-fos promoter, by replacing the BglII/HindIII fragment (Fig. 1), containing the globin 3'-UTR, with the entire LDH-A 3'-UTR. The resulting chimeric minigene (pRc/FBB/LDH) was stably transfected into rat C6 glioma cells. After serum deprivation of cells for 25-30 h, the c-fos promoter was pulse-induced with fetal calf serum resulting in a brief pulse of transcription of chimeric beta -globin/ldh mRNA. Nuclear run-off assays indicated a rapid induction of nuclear chimeric globin/ldh transcripts at 15 min (Table I). After 1 h the level of transcription had already decreased to levels seen before serum stimulation. Similar transient kinetics were observed without or with added DG or (Sp)-cAMPS. Because nuclear transcription had essentially ceased after 1 h, RNA was subsequently isolated at various time points, and the rate of decay and the half-life of chimeric beta -globin/ldh mRNA were determined using quantitative ribonuclease protection assays. As expected from our previous studies (5), wild-type beta -globin mRNA was remarkably stable (Fig. 2A, wt Globin) and decayed with a half-life of about 21 h (extrapolated from Fig. 2B). In marked contrast, chimeric beta -globin/ldh mRNA in unstimulated cells (Fig. 2A, Control) decayed at a much faster rate (t1/2 approx  65 min) (Fig. 2B) similar to the half-life of wild-type LDH-A mRNA rate (t1/2 approx  55 min) in glioma cells (1, 3).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1.   Plasmid pRc/FBB used for the construction of vectors containing LDH-A 3'-UTR fragments (see text for details). c-fos SRE represents the serum-inducible c-fos promoter element.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Nuclear run-off analysis of chimeric globin/ldh mRNA transcription rates after serum stimulation of transfected rat C6 glioma cells
C6 glioma cells were stably transfected with pRc/FBB/LDH. Serum was withdrawn for 24-28 h, after which serum and effector agents were added. At the indicated times after addition, nuclei were isolated and allowed to incorporate [alpha -32P]UTP. RNA was isolated, purified, and hybridized to 2-aminophenylthioether filters carrying immobilized globin cDNA in Bluescript or wild-type pBluescript (1). Hybridized radioactivity was eluted from the filters and determined by liquid scintillation counting. Nonspecific hybridization to wild-type pBluescript filters was subtracted from the counts/min hybridized to globin filters. RNA synthesis results are given as the means ± S.E. determined from four separate experiments.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2.   Decay of chimeric globin/ldh mRNA as a function of time. Rat C6 glioma cells were stably transfected with plasmid pRc/FBB/LDH in which the entire beta -globin 3'-UTR had been deleted by restriction with BglII/HindIII and replaced with the LDH-A 3'-UTR (nt 1103-1610). After addition of serum and effector agents, RNA was isolated at various time points up to 12 h. Globin/ldh mRNA decay was assayed by ribonuclease protection assay, and half-lives were determined as described under "Experimental Procedures." A, autoradiographs showing the decay of globin/ldh mRNA in untreated cells (Control), and cells treated with DG (200 nM), (Sp)-cAMPS (0.1 mM), and a combination of DG and (Sp)-cAMPS. GAPDH was used as internal control. The decay of wild-type globin mRNA (wt Globin) is shown for comparison. B, radioactivity was quantified using a BAS III FUJI radioanalytic imaging scanner. The results were plotted using nonlinear regression analysis with the InPlot program. Values are expressed as percentage of zero time. Values shown in B are the averages of five identical experiments and are normalized to the control expression level of GAPDH. black-triangle, control; open circle , DG-treated cells; +, (Sp)-cAMPS-treated cells; , DG+(Sp)-cAMPS-treated cells; black-square, wild-type beta -globin mRNA.

Stability of the Chimeric beta -Globin/ldhmRNA Is Mediated Synergistically via the Protein Kinase A and C Signal Pathways-- To examine the effect of protein kinase activation on the rate of decay of beta -globin/ldh mRNA, we used the Sp-isomeric form of adenosine 3', 5' cyclic monophosphorothioate ((Sp)-cAMPS), a potent activator of PKA, and DG, a membrane-permeable diacylglycerol analog that activates PKC (20) and mimicks the effect of endogenous diacylglycerol on PKC (21, 22). As shown in Fig. 2A, DG as well as (Sp)-cAMPS achieved a marked stabilization of chimeric beta -globin/ldh mRNA (Fig. 2A, compare Control with DG and (Sp)-cAMPS). Activation of PKC increased the half-life of globin/ldh mRNA from about 65 min in untreated to 4.2 h in TPA- and 3.9 h in DG-treated cells (Fig. 2B). Activation of PKA with (Sp)-cAMPS achieved an approximate 7-fold increase of the half-life of beta -globin/ldh mRNA from 65 min to 8 h (Fig. 2B).

In view of our previous identification of a synergistic action of PKA and PKC on LDH-A mRNA stability (3), we examined whether such an effect also occurred when the chimeric beta -globin/ldh 3'-UTR minigene was the transcribed template. Our data show that synergism was, indeed, demonstrable when a combination of DG + (Sp)-cAMPS was used as activators of the protein kinase pathways (Fig. 2A, DG + (Sp)-cAMPS). The half-life of beta -globin/ldh mRNA increased 18-fold to a half-life of about 21 h (extrapolated from Fig. 2B). We conclude from the data that the stability of beta -globin/ldh mRNA in glioma cells is similar or identical to wild-type LDH-A mRNA. Furthermore, the decay patterns of chimeric beta -globin/ldh mRNA in protein kinase-activated cells appear to follow mechanisms identical to wild-type LDH-A mRNA.

Inhibitors of Protein Kinase C and A Abolish the mRNA Stabilizing Effect-- To further test the pivotal role of protein kinase activation in regulation of beta -globin/ldh mRNA stability, we used inhibitors that prevent activation of the respective protein kinase pathway. Exposure of transfected cells to various activators and inhibitors of PKA and PKC markedly modified the half-life of beta -globin/ldh mRNA. As shown in Table II, the phorbol ester TPA, which binds to and activates PKC irreversibly (23), caused an approximate 4-fold increase of beta -globin/ldh mRNA half-life. Because TPA may possibly achieve this effect through mechanisms other than activation of PKC (24), we chose DG as activator. DG is a synthetic cell membrane-permeable analog of diacylglycerol, the endogenous activator of PKC, and mimicks the effect of endogenous diacylglycerol (21, 22). Indeed, DG treatment of transfected glioma cells increased the half-life of beta -globin/ldh mRNA about 4-fold. The alpha -isomeric form of phorbol 12beta ,13alpha -didecanoate, which is unable to activate PKC (25, 26), lacked the stabilizing effect of TPA on globin/ldh mRNA, strongly suggesting that TPA exerts its effect through activation of PKC. Furthermore, to prevent activation of PKC, we used the specific PKC inhibitor bisindolylmaleimide GF 109203X (BIM) (27). The use of BIM alone did not change the half-life of globin/ldh mRNA. In combination with DG or TPA, BIM prevented stabilization of the mRNA. We have already previously shown that the use of (Rp)-cAMPS, which prevents activation of PKA, similarly failed to cause stabilization of chimeric globin/ldh mRNA (3, 5).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Effect of activators and inhibitors of protein kinases A and C on stability regulation of chimeric globin/ldh mRNA
C6 glioma cells were stably transfected with pRc/FBB in which the globin 3'-UTR was replaced with the entire LDH 3'-UTR fragment. Experiments were carried out at about 90% confluence. Serum was withdrawn for 24-28 h, after which serum and effector agents were added. One hour after the addition (taken as 0 h time point), RNA was isolated at various time points up to 12 h. For further details see "Experimental Procedures." Results are expressed as the means and S.E. of four separate experiments. PD, phorbol 12beta -13alpha -didecanoate.

Systematic Analysis of LDH-A 3'-UTR for the Presence of Protein Kinase C-stabilizing Region(s)-- LDH-A mRNA is characterized by a moderately short half-life of approximately 55 min (1). Sequence analysis of its 3'-UTR identifies a 99-nucleotide domain (nt 1450-1549) that is relatively AU-rich when compared with the overall nucleotide composition of the 3'-UTR. Recently, we have shown that the 3'-UTR imparts a relatively short half-life to LDH-A mRNA because of the presence of three determinants of instability (5). Although two of the instability regions are not regulated, one of them, the 22-base 3'-UTR region comprised of nt 1478-1499, is subject to regulation by the PKA signal pathway. Its presence is an absolute requirement for cAMP-mediated stabilization of LDH-A mRNA. Using an experimentally similar approach, we now identified putative region(s) within the LDH-A 3'-UTR that are responsible for PKC-mediated stabilization of LDH-A mRNA. Our strategy consisted of the synthesis of two types of chimeric globin/ldh 3'-UTR vectors. First, we constructed a series of globin/ldh 3'-UTR vectors that contained (a) systematically truncated wild-type 3'-UTR fragments; (b) mutated 3'-UTR fragments; and (c) 3'-UTRs from which we had deleted short base regions. The deleted regions were of approximately similar size to prevent artifactual effects because of drastic variations in mRNA size. The fragments were inserted into the unique BglII site of pRc/FBB located at the junction of the beta -globin translated and 3'-untranslated regions (Fig. 1) (28). In the second approach, the entire globin 3'-UTR was deleted by restriction at the BglII/HindIII sites (Fig. 1) and replaced with wild-type and various mutated LDH-A 3'-UTR fragments. Upon stable transfection and transcription of the appropriate vectors, unique chimeric globin/ldh mRNAs were produced whose stability was assayed by ribonuclease protection assay. Because in each vector the promoter (c-fos) and globin translation region are identical, the transcripts differ from each other only in their 3'-UTR sequence.

The basal half-lives of truncated wild-type chimeric globin/ldh mRNAs are shown in Table III. Whereas several chimeric mRNAs were stable over the time course of the decay period, others exhibited a relatively short half-live without being affected by DG. However, fragment 1471-1502 (and fragment 1463-1502) appears to contain a PCSR, because treatment of cells with DG resulted in a marked stabilization of the chimeric mRNA (Table III). Interestingly, although a synergistic stabilizing response was observed with chimeric mRNA in which LDH-A 3'-UTR replaced the entire globin 3'-UTR (Figs. 1 and 2), no synergism was observed with any of the mRNAs containing a truncated fragment (data not shown).

                              
View this table:
[in this window]
[in a new window]
 
Table III
Effect of dioctanoylglycerol on the half-life of chimeric globin/ldh mRNAs with inserted LDH-A 3'-UTR fragments
Rat C6 glioma cells were stably transfected with pRc/FBB in which the listed fragments of LDH-A 3'-UTR (with 5' and 3' BglII ends) had been inserted into the BglII site of pRc/FBB (see Fig. 1). After stimulation of cells with 200 nM DG, the half-lives were determined as described under "Experimental Procedures." Results are expressed as the means and S.E. of four separate experiments. The half-life of chimeric mRNA transcribed from pRc/FBB/LDH in which globin 3'-UTR had been replaced with the complete LDH 3'-UTR (nt 1103-1610) is given for comparison.

Whereas the above data were obtained by insertion of truncated 3'-UTR fragments into the BglII site of the globin gene, further analysis was carried out by replacement of the entire globin 3'-UTR with short overlapping fragments generated from the nt 1453-1527 region. This strategy was aimed at preventing any potential artifactual effects on chimeric mRNA stability because of the presence of the globin 3'-UTR. DG-mediated stabilizing activity was analyzed, and the half-lives of the resulting chimeric globin/ldh mRNAs are summarized in Table IV. Comparison of chimeric mRNA derived from insertion of fragment 1463-1527 into pRc/FBB (Table III) with chimeric mRNA in which fragment 1463-1527 replaced globin 3'-UTR (Table IV) showed not only similar half-lives but also similar stabilizing effects of DG. Identical results were obtained when the functional characteristics (insertion versus replacement) of other fragments were compared. Based on these data, the fragment consisting of nt 1463-1502 is the shortest base region so far identified required for PKC-mediated mRNA stabilization consistent with the data listed in Table III.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Effect of dioctanoylglycerol on the half-life of chimeric globin/ldh mRNAs
The BglII/HindIII fragment containing the entire globin 3'-UTR in pRc/FBB (see Fig. 1) was deleted and replaced with the listed fragments of LDH-A 3'-UTR (with 5' BglII and 3' HindIII ends). Rat C6 glioma cells were stably transfected with these vectors and stimulated with 200 nM DG, and RNA decay was assayed as described under "Experimental Procedures." Results are expressed as the means and S.E. of four separate experiments.

Identification of the Location of the Protein Kinase C Stabilizing Region by Deletion Analysis-- To confirm and expand the above findings, we analyzed the stability of globin/ldh mRNAs in which short sequences had been systematically deleted from the 3'-UTR (Fig. 3). The resulting 3'-UTRs were inserted into the BglII site of pRc/FBB. The vectors were transfected and transcribed, followed by analysis of the decay characteristics of the chimeric mRNAs. The results are shown in Table V. Four 3'-UTRs lacking base regions located between nt 1286-1462 and 1527-1580 retained DG responsiveness. On the other hand, when fragments consisting of either nt 1453-1527, 1463-1482, or 1478-1506 were deleted, two of the chimeric globin/ldh mRNAs, with deletions at nt 1453-1527 and 1478-1506, exhibited relatively higher basal half-lives, whereas the globin/ldh mRNA with a deletion of nt 1463-1482 did not. However, none of the corresponding chimeric globin/ldh mRNAs were stabilized by DG, indicating that the deleted fragments contained the complete or at least part of the PKC-responsive site. These data allow location of the PKC-responsive site within nucleotides 1453-1506.

                              
View this table:
[in this window]
[in a new window]
 
Table V
Effect of dioctanoylglycerol on the half-life of chimeric globin/ldh mRNAs containing LDH-A 3'-UTR fragments with partial deletions
The BglII/HindIII fragment in pRc/FBB (see Fig. 1) was deleted and replaced with LDH-A 3'-UTR from which the listed fragments had been deleted. Rat C6 glioma cells were stably transfected with these vectors. After stimulation of cells with 200 nM DG, the half-lives were determined as described under "Experimental Procedures."

A 20-Nucleotide 3'-UTR Region Is Responsible for Stability Regulation-- To achieve an even more precise delineation of the active PKC-responsive site, mutational analysis was carried out. We introduced several mutational changes into fragment 1453-1502, which, based on above data, contains the region required for PKC-mediated mRNA stabilization. The resulting chimeric mRNAs were analyzed for DG responsiveness. The data are shown in Table VI. Deletion of a -UAA- triplet at nt 1464-1466 (mut1) as well as deletion of two bases at nt 1470-1471 (-UU-) (mut2) did not change the stabilizing effect of DG. Mutation of bases at 1486-1490 from -CUGUA- to -GACAG- (mut3) maintained the stabilizing effect although to a somewhat lesser degree. Mutation 4, synthesized from mut3 by deletion of a -UU- doublet at 1484-1485 did not respond to DG stimulation and lacked the stabilizing effect. A change of the doublet -UU-at nt 1491-1492 (mut 5) to -GG- did not affect DG responsiveness. When wild-type fragment 1453-1520 was inserted into pRc/FBB in the reverse orientation, the instability effect as well as DG responsiveness were not observed, indicating that the destabilizing and regulatory effects required a specific sequence polarity. Thus, mutations introduced upstream of nt 1472 (for instance at nt 1464-1466 and 1470-1471) (see Table VI) did not abolish stabilization. Similarly, deletion of sequences downstream of nt 1492 (see Table IV and V) showed no effect allowing the conclusion that the region encompassing bases 1472-1491 represents the nucleotide sequence required for stabilization of LDH-A mRNA via the PKC pathway.

                              
View this table:
[in this window]
[in a new window]
 
Table VI
Effect of mutational changes within LDH-A 3'-UTR fragment 1453-1520 on DG-mediated stabilization of chimeric globin/ldh mRNAs
Rat C6 glioma cells were stably transfected with pRc/FBB in which the listed wild-type (wt) and mutated fragments (mut) had been inserted into the BglII site of pRc/FBB (see Fig. 1). Cells were stimulated with 200 nM DG. After isolation of RNA, mRNA decay was determined as described under "Experimental Procedures." Results are expressed as the means and S.E. of four separate experiments. The sequences of the wild-type (wt) and mutated (mut) fragments are: 1453-1520 wt, 5'-AUCUUGUGCAUAAAUGUUCUACAGGAUAUUUUCUGUAUUAUAUGUGUCUGUAGUGUACAUUGCAAUA-3'; mut1, 5'-AUCUUGUGCA-AUGUUCUACAGGAUAUUUUCUGUAUUAUAUGUGUCUGUAGUGUACAUUGCAAUA-3'; mut2, 5'-AUCUUGUGCAUAAAUG-CUACAGGAUAUUUUCUGUAUUAUAUGUGUCUGUAGUGUACAUUGCAAUA-3'; mut3, 5'-AUCUUGUGCAUAAAUGUUCUACAGGAUAUUUUGACAGUUAUAUGUGUCUGUAGUGUACAUUGCAAUA-3'; mut4, AUCUUGUGCAUAAAUGUUCUACAGGAUAUU-GACAGUUAUAUGUGUCUGUAGUGUACAUUGCAAUA-3'; mut5, 5'-AUCUUGUGCAUAAAUGUUCUACAGGAUAUUUUCUGUAGGAUAUGUGUCUGUAGUGUACAUUGCAAUA-3'. A dash indicates base deletion; a bold letter indicates a mutated base.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Our results strongly support a role for the PKC signal pathway in the mechanism of LDH-A mRNA stabilization and identify a critical nucleotide sequence in LDH-A 3'-UTR that is required for PKC-mediated LDH-A mRNA stabilization. The most critical domain is comprised of nucleotides 1472-1486, although a somewhat larger region extending to nucleotide 1491 is required to express the full magnitude of the stabilizing effect. The region consists of a relatively U-rich (48%) 20-base sequence -CUACAGGAUAUUUUCUGUAU-, which destabilizes beta -globin mRNA and responds to PKC activation with a marked mRNA stabilization. Based on its characteristics, we have named the 20-base fragment PCSR. Thus, the most significant result described above consists of the identification of a region (nt 1472-1491) with a dual function: (a) it is a determinant of LDH-A mRNA instability and (b) it functions specifically as a modulator of LDH-A mRNA half-life depending on the state of activation of PKC.

Perhaps the most surprising finding to come from our work is that CSR and PCSR contain a 13-nt region (nt 1478-1491; -AUAUUUUCUGUAU-) that is common to both regulatory elements (Fig. 4). Because the 13 nucleotides constitute 59% of the CSR and 65% of the PCSR, respectively, the question arises as to the significance of the overlapping arrangement of these two stabilizing regions within the 3'-UTR. One functional property common to both CSR and PCSR, namely destabilization of LDH-A mRNA, is also exhibited by a class of short-lived mRNAs that share consensus-like AU-rich motifs in their 3'-UTR (7). Although AU-rich motifs appear to mark mRNA in general for rapid degradation, it is unlikely that relative nonspecific AU-rich sequences will participate in the selective regulation of mRNA stability, such as observed, for instance, for mRNAs that are under post-transcriptional control by certain effector agents (e.g. cAMP and DG). Rather, determinants in CSR and PCSR, other than the 13-nt common sequence, seem to be required to modulate stability specifically in response to the PKA and PKC signal pathways. In this fashion the stability and its regulation will be controlled in a dual mode by relatively nonspecific AU-rich sequences that determine the relative instability/stability of the mRNA and by sequence domains that will determine the specificity of the stabilizing response. Thus, we hypothesize that part of the LDH-A 3'-UTR is composed of two discrete module(s): (a) the 13-nt overlapping nonspecific AU-rich determinant in PCSR and CSR and (b) specific site(s) that in concert with phospho/dephosphoproteins are instrumental in determining the specificity of the stabilizing response. These ideas are supported by our recent identification of four proteins whose specific CSR binding and mRNA stabilizing effects are achieved through their phosphorylative modification by PKA (4) in concert with phosphoprotein phosphatases. Efforts are underway to identify putative PCSR-binding protein(s) and to analyze their functional properties.


View larger version (8K):
[in this window]
[in a new window]
 
Fig. 3.   Schematic representation of wild-type and mutant LDH-A 3'-UTRs in pRc/FBB/LDH. The base numbers of deleted fragments containing the PKC-responsive region are shown in bold type.


View larger version (7K):
[in this window]
[in a new window]
 
Fig. 4.   Homologous bases in CSR and PCSR. The CSR and PCSR are lined up to show the 13-nucleotide homology. Homologous bases are underlined.

Our demonstration of a synergism involving PKA/PKC-mediated LDH-A mRNA stabilization is particularly intriguing (Fig. 2) (3). Importantly, the effect could be duplicated with a chimeric globin/ldh mRNA, provided the transcribed chimeric globin/ldh minigene contained the entire wild-type LDH-A 3'-UTR. Truncated 3'-UTR fragments, even though they contain both the CSR and PCSR, lacked the synergistic effect, and simultaneous activation of PKA and PKC achieved only an additive increase of globin/ldh mRNA half-life. Although the PCSR and CSR are necessary to achieve message stabilization, their presence alone appears not to be sufficient to obtain a cooperative response, and our results do not rule out the possibility that secondary structure or other sequences within LDH-A 3'-UTR may play a role in achieving a synergism. Nevertheless, synergism suggests a "cross-talk" between the two signal transduction systems involving trans-regulatory RNA-binding proteins that are substrates and targets for both PKA and PKC. Cross-talk between two major signal transduction pathways is a well recognized phenomenon known to occur in a number of systems (29-31). A mechanism for the two cell surface receptor coupled signal transduction pathways (PKA and PKC) has been suggested previously (32). It depends on the presence of serines and threonines that are specific sites of phosphorylation for different protein kinases. As mentioned above, our previous studies have identified several RNA-binding proteins (CSR-BP) that specifically interact with the CSR and are instrumental in regulating stability (4). Because CSR and PCSR possess a 13-nt region in common, the distinct possibility arises that one or more of the CSR-binding proteins are also substrates for PKC and may be mechanistically involved in the cooperative effect. However, the understanding of the molecular mechanism of PKA and PKC-regulated mRNA stability must come from the cloning of cDNAs encoding the RNA-binding proteins.

A great number of examples of regulated mRNA stability (up- and down-regulation) in eukaryotic cells by phorbol ester or corresponding second messengers (such as DG) are known (7, 10, 33-44). Although these studies indicate that an increased level of phorbol ester is a sufficient signal for increased mRNA stability, the molecular mechanisms mediating the effects of phorbol ester have largely remained obscure. The fact that phorbol ester can activate PKC has led to the notion that mRNA stability regulation results from a cascade of events involving PKC isoenzymes and a stabilizing/destabilizing regulatory system such as cis-and trans-acting factors. Phosphorylative modification of specific RNA binding proteins would achieve the fine tuning of mRNA half-life. In the case of LDH-A mRNA, the use of a specific inhibitor of PKC, bisindolylmaleimide, can abrogate the effect of TPA or diacylglycerol on mRNA stability, indicating the involvement of PKC in the stabilization mechanism. These findings are in agreement with previous reports demonstrating that the stability of ribonucleotide reductase R1 mRNA is increased after phorbol ester treatment of cells. This phenomenon appears to be mediated through a 49-nt cis-elements in the 3'-UTR of ribonucleotide preductase mRNA and its interaction with specific binding proteins (45). A search for sequence similarities between PCSR and the PKC regulated ribonucleotide reductase R1 has identified a 3'-UTR region (46) revealing marked sequence similarities (80% homology) (identical bases are printed in bold): LDH-A, UUGUGC -AUAAAUG - UUCUACAG - GAUA (nt 1457-1480), and R1, UUUUGAAAUAAACAUUUCUA - AGUGAUA (nt 2876-2902).

Protein kinase C is a family of at least 10 isoenzymes, all having closely related structure but differing in their individual functional properties (23, 24). Rat C6 glioma cells express mainly the alpha , delta , epsilon , and zeta  isoforms (47). The alpha , delta  and epsilon  forms are activated by phorbol ester and inhibited by bisindolylmaleimide. Thus, one or more of these three isoforms may mediate the stability regulation of PKC. We are presently investigating the precise nature of the isoenzyme(s) involved in mRNA stabilization.

Finally, it is appropriate to briefly discuss the physiological significance and implications of our findings. LDH plays a pivotal role in normal anaerobic glycolysis. Analysis of the LDH isoenzyme patterns in different cell types under a variety of physiological conditions suggests complex regulatory mechanism. The patterns are subject to regulation by a number of different effector agents, including 17beta -estradiol (48, 49), epidermal growth factor (50, 51), catecholamines (1, 52), phorbol ester (2, 3), hypoxia (53, 54), and c-Myc (55). These agents almost exclusively change the isoenzyme pattern in favor of the homotetrameric (A4) isoenzyme LDH-5. The shifts are attributed to a need for increased A subunit-containing isoenzymes that are optimally adapted for anaerobic function. LDH-5 has a low Km for pyruvate and a high Vmax. It can derive more energy for the anaerobic cell by reducing pyruvate to lactate with a concomitant generation of NAD+. These situations can occur, for instance, under conditions of stress-induced activation of beta -adrenergic receptors by epinephrine, by hypoxia, phorbol ester- or c-Myc-induced tumorigenesis, or in tumor cells whose altered metabolic profiles require a high rate of glucose uptake and increased glycolysis (56, 57). Complex interrelationships exist between these signals that regulate LDH-A expression. For instance, evidence has been provided for an interaction of the PKA and PKC pathways (58-61). In systems in which cAMP is mitogenic, it enhances the expression of c-Myc (62-64) which, in turn, induces LDH-A expression (55). Furthermore, hypoxic induction of LDH-A has been functionally linked to PKA activation involving the CRE and CREB (53, 65). Concomitantly with these events, activation of PKA leads to a series of amplification cascades that ultimately lead to increased blood glucose levels and transport (66, 67), conditions that have to be satisfied for increased glycolysis and lactate production by tumor and hypoxic cells.

    ACKNOWLEDGEMENT

We thank Delai Huang for excellent technical assistance.

    FOOTNOTES

* This work was supported by Grant GM53115 from the National Institutes of Health and Neuroscience Training Grant T32NS07140 (to D. T.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Cell and Molecular Biology, Northwestern University Medical School, 303 E. Chicago Ave., Chicago, IL 60611. Tel.: 312-908-5275; Fax: 312-503-7107; E-mail: rjungman@nwu.edu.

    ABBREVIATIONS

The abbreviations used are: LDH or ldh, lactate dehydrogenase; UTR, untranslated region; CSR, cAMP-stabilizing region; PCSR, protein kinase C-stabilizing region; nt, nucleotide(s); (Sp)-cAMPS, adenosine 3', 5' cyclic monophosphorothioate; TPA, 12-0-tetradecanoylphorbol-13-acetate; DG, dioctanoylglycerol; PKA, protein kinase A; PKC, protein kinase C; BIM, 3-[1-(3-dimethylaminopropyl)-indol-3-yl]-3-(indol-3-yl)-maleimide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Jungmann, R. A., Kelley, D. C., Miles, M. F., and Milkowski, D. M. (1983) J. Biol. Chem. 258, 5312-5318[Abstract/Free Full Text]
2. Huang, D., and Jungmann, R. A. (1995) Mol. Cell. Endocrinol. 108, 87-94[CrossRef][Medline] [Order article via Infotrieve]
3. Huang, D., Hubbard, C. J., and Jungmann, R. A. (1995) Mol. Endocrinol. 9, 994-1004[Abstract/Free Full Text]
4. Tian, D., Huang, D., Brown, R. C., and Jungmann, R. A. (1998) J. Biol. Chem. 273, 28454-28460[Abstract/Free Full Text]
5. Tian, D., Huang, D., Short, S., Short, M. L., and Jungmann, R. A. (1998) J. Biol. Chem. 273, 24861-24866[Abstract/Free Full Text]
6. Short, M. L., Huang, D., Milkowski, D. M., Short, S., Kunstman, K., Soong, C-J., Chung, K. C., and Jungmann, R. A. (1994) Biochem. J. 304, 391-398
7. Ross, J. (1995) Microbiol. Rev. 59, 423-450[Abstract/Free Full Text]
8. Peng, H., and Lever, J. E. (1995) J. Biol. Chem. 270, 23996-24003[Abstract/Free Full Text]
9. Peng, H., and Lever, J. E. (1995) J. Biol. Chem. 270, 20536-20542[Abstract/Free Full Text]
10. Ahern, S. M., Miyata, T., and Sadler, J. E. (1993) J. Biol. Chem. 268, 2154-2159[Abstract/Free Full Text]
11. Levine, R. A., McCormack, J. E., Buckler, A., and Sonesheim, G. E. (1986) Mol. Cell. Biol. 6, 4112-4116[Abstract/Free Full Text]
12. Mitchell, R. L., Zokas, L., Schreiber, R. D., and Verma, I. M. (1985) Cell 40, 209-217[CrossRef][Medline] [Order article via Infotrieve]
13. Chen, M., Schnermann, J., Smart, A. M., Brosius, F. C., Killen, P. D., and Briggs, J. P. (1993) J. Biol. Chem. 268, 24138-24144[Abstract/Free Full Text]
14. Hod, Y., and Hanson, R. W. (1988) J. Biol. Chem. 263, 7747-7752[Abstract/Free Full Text]
15. Shyu, A.-B., Greenberg, M. E., and Belasco, J. G. (1989) Genes Dev. 3, 60-72[Abstract/Free Full Text]
16. Shaw, G., and Kamen, R. (1986) Cell 46, 659-667[CrossRef][Medline] [Order article via Infotrieve]
17. Greenberg, M. E., and Ziff, E. B. (1984) Nature 311, 433-438[CrossRef][Medline] [Order article via Infotrieve]
18. Harrold, S., Genovese, C., Kobrin, B., Morrison, S. L., and Milcarek, C. (1991) Anal. Biochem. 198, 19-29[CrossRef][Medline] [Order article via Infotrieve]
19. Scott, W. A., and Tomkins, G. M. (1975) Methods Enzymol. 40, 273-293[Medline] [Order article via Infotrieve]
20. Berridge, M. J. (1987) Annu. Rev. Biochem. 56, 159-193[Medline] [Order article via Infotrieve]
21. Boynton, A. L., Whitfield, J. F., and Kleine, L. P. (1983) Biochem. Biophys. Res. Commun. 115, 383-386[CrossRef][Medline] [Order article via Infotrieve]
22. Lapetina, E. G., Reep, B., Ganon, B. R., and Bell, R. M. (1985) J. Biol. Chem. 260, 1358-1361[Abstract/Free Full Text]
23. Nishizuka, Y. (1984) Nature 308, 693-698[CrossRef][Medline] [Order article via Infotrieve]
24. Nishizuka, Y. (1986) Science 233, 305-312[Abstract/Free Full Text]
25. Kreibich, G., and Hecker, E. (1970) Z. Krebsforsch 74, 448-456[CrossRef][Medline] [Order article via Infotrieve]
26. Akiguchi, I., Izumi, M., and Nagataki, S. (1993) J. Endocrinol. 138, 379-389[Abstract/Free Full Text]
27. Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., Loriolle, F., Duhamel, L., Charon, D., and Kirilovsky, J. (1991) J. Biol. Chem. 266, 15771-15781[Abstract/Free Full Text]
28. van Ooyen, A., van den Berg, J., Mantei, N., and Weissmann, C. (1979) Science 206, 337-344[Abstract/Free Full Text]
29. Houslay, M. D. (1991) Eur. J. Biochem. 195, 9-27[Medline] [Order article via Infotrieve]
30. Li, Z., Vaidya, V. A., Alvaro, J. D., Iredale, P. A., Hsu, R., Hoffman, G., Fitzgerald, L., Curran, P. K., Machida, C. A., Fishman, P. H., and Duman, R. S. (1998) Mol. Pharmacol. 54, 14-21[Abstract/Free Full Text]
31. Morimoto, B. H., and Koshland, D. E., Jr. (1994) J. Biol. Chem. 269, 4065-4069[Abstract/Free Full Text]
32. Habener, J. (1990) Mol. Endocrinol. 4, 1087-1094[Abstract/Free Full Text]
33. Sachs, A. B. (1993) Cell 74, 413-421[CrossRef][Medline] [Order article via Infotrieve]
34. Shih, S.-C., Mullen, A., Abrams, K., Mukhopadhyay, D., and Claffey, K. P. (1999) J. Biol. Chem. 274, 15407-15414[Abstract/Free Full Text]
35. Izzo, N., Jr., Tulenko, T. N., and Solucci, W. S. (1994) J. Biol. Chem. 269, 1705-1710[Abstract/Free Full Text]
36. Iwai, Y., Bickel, M., Pluznik, D. H., and Cohen, R. B. (1991) J. Biol. Chem. 266, 17959-17965[Abstract/Free Full Text]
37. Lee, N. H., Earle-Hughes, J., and Fraser, C. M. (1994) J. Biol. Chem. 269, 4291-4298[Abstract/Free Full Text]
38. Ferry, R. C., Unsworth, C. D., Artymyshyn, R. P., and Molinoff, P. B. (1994) J. Biol. Chem. 269, 31850-31857[Abstract/Free Full Text]
39. Shin, K. S., Park, J. Y., Kwon, H., Chung, C. H., and Kang, M. S. (1997) J. Biol. Chem. 272, 21227-21232[Abstract/Free Full Text]
40. Bohjanen, P., Petryniak, B., June, C. H., Thompson, C. B., and Lindsten, T. (1991) Mol. Cell. Biol. 11, 3288-3295[Abstract/Free Full Text]
41. Akashi, M., Loussararian, A. H., Adelman, D. C., Saito, M., and Koeffler, H. P. (1990) J. Clin. Invest. 85, 121-129
42. Kijima, K., Matsubara, H., Murasawa, S., Maruyama, K., Ohkubo, N., Mori, Y., and Inada, M. (1996) Hypertension 27, 529-534[Abstract/Free Full Text]
43. Perrone-Bizzozero, N. I., Cansino, V. V., and Kohn, D. T. (1993) J. Cell Biol. 120, 1263-1270[Abstract/Free Full Text]
44. Pang, J.-H. S., Wu, C.-J., and Chau, L.-Y. (1996) Biochem. J. 319, 185-189
45. Amara, F. M., Hurta, R. R., Huang, A., and Wright, J. A. (1995) Cancer Res. 55, 4503-4505[Abstract/Free Full Text]
46. Chen, F. Y., Amara, F. M., and Wright, J. A. (1993) EMBO J. 12, 3977-3986[Medline] [Order article via Infotrieve]
47. Chen, C. C. (1993) FEBS Lett. 332, 169-173[CrossRef][Medline] [Order article via Infotrieve]
48. Lee, C., Oliver, L., Coe, E. L., and Oyasu, R. (1979) J. Natl. Cancer Inst. 62, 193-199
49. Li, S. S., and Hou, E. W. (1989) Cell Biol. Intl. Rep. 13, 619-624[CrossRef][Medline] [Order article via Infotrieve]
50. Matrisian, L. M., Rautmann, G., Magun, B. E., and Breathnach, R. (1985) Nucleic Acids Res. 13, 711-726[Abstract/Free Full Text]
51. Boussouar, F., and Benahmed, M. (1999) Biol. Reproduct. 61, 1139-1145[Abstract/Free Full Text]
52. Jungmann, R. A., Christensen, M. L., and Derda, D. R. (1979) in Effects of Drugs in the Cell Nucleus (Busch, H., ed) , pp. 507-519, Academic Press, Orlando, FL
53. Firth, J. D., Ebert, B. L., and Ratcliff, P. J. (1995) J. Biol. Chem. 270, 21021-21027[Abstract/Free Full Text]
54. Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., and Giallongo, A. (1996) J. Biol. Chem. 271, 32529-32537[Abstract/Free Full Text]
55. Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., and Dang, C. V. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 6658-6663[Abstract/Free Full Text]
56. Dang, C. V., and Semenza, G. L. (1999) Trends Biochem. Sci. 24, 68-72[CrossRef][Medline] [Order article via Infotrieve]
57. Warburg, O. (1956) Science 123, 309-314[Free Full Text]
58. Field, J. B., Ealey, P. A., Marshall, N. J., and Cockcrofts, S. (1987) Biochem. J. 247, 519-524[Medline] [Order article via Infotrieve]
59. Cambier, J. C., Newell, M. K., Justement, L. B., McGuire, J. C., Leach, K. L., and Chen, Z. Z. (1987) Nature 18, 629-632
60. Ziegler, A., Knesel, J., Fabbro, D., and Nagamine, Y. (1991) J. Biol. Chem. 266, 21067-21074[Abstract/Free Full Text]
61. Lombardi, A., Veneziani, B. M., Toramontano, D., and Ingbar, S. H. (1988) Endocrinology 123, 1544-1552[Abstract/Free Full Text]
62. Marcu, K. B., Bossone, S. A., and Patel, A. J. (1992) Annu. Rev. Biochem. 61, 809-860[CrossRef][Medline] [Order article via Infotrieve]
63. Pirson, I., Coulonval, K., Lamy, F., and Dumont, J. E. (1996) J. Cell. Physiol. 168, 59-70[CrossRef][Medline] [Order article via Infotrieve]
64. Tramontano, D., Chin, W. W., Moses, A. C., and Ingbar, S. H. (1986) J. Biol. Chem. 261, 3919-3922[Abstract/Free Full Text]
65. Ebert, B. L., and Bunn, H. F. (1998) Mol. Cell. Biol. 18, 4089-4096[Abstract/Free Full Text]
66. Stein, I., Neeman, M., Shweiki, D., Itin, A., and Keshet, E. (1995) Mol. Cell. Biol. 15, 5363-5368[Abstract]
67. Stephens, J. M., Carter, B. Z., Pekala, P. H., and Malter, J. S. (1992) J. Biol. Chem 267, 8336-8341[Abstract/Free Full Text]


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
N. Fukui, Y. Ikeda, T. Ohnuki, A. Hikita, S. Tanaka, S. Yamane, R. Suzuki, L. J. Sandell, and T. Ochi
Pro-inflammatory Cytokine Tumor Necrosis Factor-{alpha} Induces Bone Morphogenetic Protein-2 in Chondrocytes via mRNA Stabilization and Transcriptional Up-regulation
J. Biol. Chem., September 15, 2006; 281(37): 27229 - 27241.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Pascale, M. Amadio, G. Scapagnini, C. Lanni, M. Racchi, A. Provenzani, S. Govoni, D. L. Alkon, and A. Quattrone
Neuronal ELAV proteins enhance mRNA stability by a PKC{alpha}-dependent pathway
PNAS, August 23, 2005; 102(34): 12065 - 12070.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
T. A. Washington, J. M. Reecy, R. W. Thompson, L. L. Lowe, J. M. McClung, and J. A. Carson
Lactate dehydrogenase expression at the onset of altered loading in rat soleus muscle
J Appl Physiol, October 1, 2004; 97(4): 1424 - 1430.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Kishore, M. R. McMullen, and L. E. Nagy
Stabilization of Tumor Necrosis Factor alpha mRNA by Chronic Ethanol. ROLE OF A + U-RICH ELEMENTS AND p38 MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING PATHWAY
J. Biol. Chem., November 2, 2001; 276(45): 41930 - 41937.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
L. Olivi, J. Sisk, and J. Bressler
Involvement of DMT1 in uptake of Cd in MDCK cells: role of protein kinase C
Am J Physiol Cell Physiol, September 1, 2001; 281(3): C793 - C800.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Y. Lee, P. Loflin, C. J. Clancey, H. Peng, and J. E. Lever
Cyclic Nucleotide Regulation of Na+/Glucose Cotransporter (SGLT1) mRNA Stability. INTERACTION OF A NUCLEOCYTOPLASMIC PROTEIN WITH A REGULATORY DOMAIN IN THE 3'-UNTRANSLATED REGION CRITICAL FOR STABILIZATION
J. Biol. Chem., October 20, 2000; 275(43): 33998 - 34008.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Carpenter, D. Cordery, and T. J. Biden
Protein Kinase Cdelta Activation by Interleukin-1beta Stabilizes Inducible Nitric-oxide Synthase mRNA in Pancreatic beta -Cells
J. Biol. Chem., February 9, 2001; 276(7): 5368 - 5374.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Short, S.
Right arrow Articles by Jungmann, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Short, S.
Right arrow Articles by Jungmann, R. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement